NCT05223686 - To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 10, 2022

Primary Completion Date

June 10, 2023

Study Completion Date

March 10, 2025

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG

Human CD19-CD22 Targeted T Cells Injection

One time single predetermined dose level CAR-positive T cells will be utilized based on the NMPA approved product label.

Trial Locations (1)

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai